Global Epidiolex (Cannabidiol) Drug Insight and Market Forecasts to 2030: Trial Interventions, Trial Conditions, Trial Status, Start and Completion Dates –

DUBLIN–(BUSINESS WIRE)–The “Epidiolex (Cannabidiol) – Drug Insight and Market Forecast – 2030” report has been added to’s offering.

Epidiolex (cannabidiol) – Drug Insight and Market Forecast – 2030 report outlays comprehensive insights of the product indicated for the treatment of its approved condition.

A detailed picture of the Epidiolex (cannabidiol) in Seven Major Markets, i.e. United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product.

The product details cover mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Epidiolex significantly reduced seizures in patients with LGS and Dravet. Epidiolex has a thoroughly evaluated efficacy and safety profile. Epidiolex is FDA approved to ensure quality and consistency in every bottle. The FDA granted approval of Epidiolex to GW Research Ltd. The most common side effects that occurred in Epidiolex-treated patients in the clinical trials were: sleepiness, sedation and lethargy; elevated liver enzymes; decreased appetite; diarrhea; rash; fatigue, malaise and weakness; insomnia, sleep disorder and poor quality sleep; and infections.

In March 2020, GW Pharmaceuticals along with its U.S. subsidiary Greenwich Biosciences announced that the U.S. Food and Drug Administration (FDA) has accepted for filing with Priority Review its recently submitted supplemental New Drug Application (sNDA) for the use of Epidiolex (cannabidiol) CV to treat seizures associated with Tuberous Sclerosis Complex (TSC).

Scope of the report

The report provides insights into:

  • A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the drug marketed details across the United States, Europe and Japan.
  • The report also covers the patent’s information with expiry timeline around Epidiolex (cannabidiol).
  • The report contains historical and forecasted sales for Epidiolex (cannabidiol) till 2030.
  • Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
  • The report also features the SWOT analysis with analyst insights and key findings of Epidiolex (cannabidiol).

Epidiolex (cannabidiol) Analytical Perspective

In-depth Epidiolex (cannabidiol) Market Assessment

This report provides a detailed market assessment of Epidiolex (cannabidiol) in Seven Major Markets, i.e. United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

Epidiolex (cannabidiol) Clinical Assessment

The report provides the clinical trials information of Epidiolex (cannabidiol) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights

  • In the coming years, the market scenario for Epidiolex (cannabidiol) is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Epidiolex (cannabidiol) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Other approved products for the disease are giving market competition to Epidiolex (cannabidiol) and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Epidiolex (cannabidiol).
  • Our in-depth analysis of the sales data of Epidiolex (cannabidiol) from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Epidiolex (cannabidiol) in the market.

Key Questions Answered

  • What is the prescribed dosage and strengths of Epidiolex (cannabidiol) are available in the market?
  • What are the common adverse reactions or side effects of Epidiolex (cannabidiol)?
  • What is the product type, route of administration and mechanism of action of Epidiolex (cannabidiol)?
  • What are the chemical specifications of Epidiolex (cannabidiol)?
  • How are the clinical trials diversified on the basis of the trial status?
  • What is the history of Epidiolex (cannabidiol), and what is its future?
  • What are the marketed details of Epidiolex (cannabidiol) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • How many patents have been granted to Epidiolex (cannabidiol) and when these patents will get expire?
  • What are the pros (benefits) and cons (disadvantages) of Epidiolex (cannabidiol)?
  • In which countries Epidiolex (cannabidiol) got approval and when it gets launched?
  • What are the clinical trials are currently ongoing for Epidiolex (cannabidiol)?
  • How the safety and efficacy results determined the approval of Epidiolex (cannabidiol)?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Epidiolex (cannabidiol) development?
  • What are the key designations that have been granted to Epidiolex (cannabidiol)?
  • What is the historical and forecasted market scenario of Epidiolex (cannabidiol)?
  • How is the market trend of Epidiolex (cannabidiol) is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
  • What are the other approved products available and how these are giving competition to Epidiolex (cannabidiol)?
  • Which are the late-stage emerging therapies under development for the treatment of the indicated condition?

For more information about this report visit

Latest posts